Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FHTX
FHTX logo

FHTX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Foghorn Therapeutics Inc (FHTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.150
1 Day change
2.47%
52 Week Range
6.950
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Foghorn Therapeutics Inc (FHTX) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks significant positive catalysts, has no recent trading signals from Intellectia Proprietary Trading Signals, and exhibits neutral technical and trading trends. Additionally, there is no recent news, congress trading data, or financial performance insights to support a buy decision. Given the lack of compelling data, holding off on investment in FHTX is recommended.

Technical Analysis

The MACD is positive and expanding, indicating a bullish signal. RSI is neutral at 63.258, and moving averages are converging, showing no clear trend. The stock is trading near its R1 resistance level of 4.217, which may act as a barrier to further upward movement. Overall, the technical indicators suggest a neutral to slightly bullish trend.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The implied volatility is extremely high (728.61), with an IV rank of 105.89, suggesting significant uncertainty. However, the low put-call ratios and zero option volume indicate a lack of active trading sentiment.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
5

Positive Catalysts

  • NULL identified. There is no recent news, congress trading data, or significant insider or hedge fund activity.

Neutral/Negative Catalysts

  • The stock has a 60% chance of declining in the next day (-0.11%), week (-0.66%), and month (-3.92%) based on historical candlestick patterns. Additionally, the lack of trading signals and high implied volatility may deter long-term investors.

Financial Performance

No financial data available for analysis. The latest quarter's performance could not be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for FHTX, leaving a gap in understanding Wall Street sentiment.

Wall Street analysts forecast FHTX stock price to rise
9 Analyst Rating
Wall Street analysts forecast FHTX stock price to rise
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.050
sliders
Low
9
Averages
11.38
High
14
Current: 4.050
sliders
Low
9
Averages
11.38
High
14
Jefferies
Buy
downgrade
$14 -> $12
AI Analysis
2026-02-17
Reason
Jefferies
Price Target
$14 -> $12
AI Analysis
2026-02-17
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Foghorn Therapeutics (FHTX) to $12 from $14 and keeps a Buy rating on the shares while taking over lead coverage of the stock. FHD-909, Foghorn's lead clinical asset partnered with Eli Lilly (LLY), has topline Phase 1 dose-escalation data along with a go/no-go decision on dose-expansion expected mid-2026 and the firm could see a 80% higher or 40% lower move on that data, the analyst tells investors.
BTIG
Buy
initiated
$11
2025-12-18
Reason
BTIG
Price Target
$11
2025-12-18
initiated
Buy
Reason
BTIG initiated coverage of Foghorn Therapeutics with a Buy rating and $11 price target. The firm says Foghorn is a clinical-stage biopharmaceutical company developing novel inhibitors and degraders for various oncology indications. BTIG views the shares undervalued into the company's Phase 1 data in 2026. The share setup is favorable into the readout for FHD-909, a "potent and selective" inhibitor of SMARCA2 currently in Phase 1a dose escalation for solid tumors, BTIG contends.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FHTX
Unlock Now

People Also Watch